Bioniche Life Sciences Inc. announced that it has engaged Evercore Partners Inc. to assist the board of directors and management in its divestment of the Animal Health business. As Evercore leads its work on the Animal Health side of the business, the company is actively engaged in discussions with potential partners for its Phase III bladder cancer product, Urocidin, which will unlock value for the company's Bioniche Therapeutics Corp. subsidiary.

Epsilon Energy Ltd. (Canada) (TSX:EPS) did not receive a proposal as of the May 10, 2013 deadline under its strategic alternative process. “We entered into the review of strategic alternatives from a position of strength, in terms of both robust Marcellus upstream and midstream operations and cash flow,” Zoran Arandjelovic, Chairman and Chief Executive Officer of Epsilon, said in a news release. “The process over the past three months, although not resulting in an acceptable offer for the whole of the company, did highlight the quality of our Marcellus asset base and continued shareholder value growth opportunities. Although the board believes the company and its shareholders are best served by our continued focus on the development of upstream and midstream assets, it remains open minded to all alternatives that would enhance shareholders value.” Evercore Partners Inc., financial advisor of Epsilon, will continue to deal with interested parties for the proposal that deems in the best interest of Epsilon and its shareholders.

Bioniche Life Sciences Inc. (TSX:BNC) has engaged Evercore Partners Inc. (NYSE:EVR) to assist the Board of Directors and management in the sale of its animal health business. "Evercore's track record in successfully negotiating such transactions and its extensive network of contacts in the animal health industry make it an ideal firm to lead this exercise", said James Rae, the Chairman of Bioniche Life Sciences.